bupropion has been researched along with Depression in 152 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The search terms included: "AXS-05" OR "dextromethorphan and bupropion" AND "depression"." | 9.41 | Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. ( Akbar, D; Cao, B; Ceban, F; Ho, R; Kwan, ATH; McIntyre, RS; Rhee, TG; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2023) |
| "A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue." | 9.34 | A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020) |
| "In treatment of depression with less than optimal response, augmentation with either aripiprazole or bupropion was cost-effective relative to switching to bupropion." | 9.27 | Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. ( Johnson, GR; Mohamed, S; Park, A; Scrymgeour, A; Yoon, J; Zisook, S, 2018) |
| "While the combination therapy of varenicline and sustained release bupropion (bupropion SR) for cigarette smoking cessation can increase smoking abstinence rates, it has also been associated with increases in self-reported depressive symptoms." | 9.20 | Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. ( Ebbert, JO; Elrashidi, MY; Hong, AS; Schroeder, DR, 2015) |
| "The efficacy, safety, and tolerability of combined bupropion versus placebo using duloxetine as active reference drug, in patients with a DSM-IV diagnosis of major depression with atypical features and a history of treatment resistance, were evaluated in this preliminary six-week study." | 9.19 | Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. ( De Berardis, D; De Pasquale, C; Fornaro, M; Fornaro, P; Iasevoli, F; Martino, M; Mattei, C; Mungo, S; Prestia, D; Vinciguerra, V, 2014) |
| "To assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning." | 9.17 | Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. ( Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW, 2013) |
| "Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers." | 9.16 | Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. ( Ahluwalia, JS; Benowitz, NL; Choi, WS; Cox, LS; Faseru, B; Mayo, MS; Nollen, NL; Okuyemi, KS; Tyndale, RF, 2012) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 9.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "Bupropion and cognitive-behavioral treatment (CBT) for depression have been used as components of treatments designed to alleviate affective disturbance during smoking cessation." | 9.14 | Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. ( Abrantes, AM; Brown, RA; Kahler, CW; Leventhal, AM; Lloyd-Richardson, E; Niaura, R; Strong, DR, 2009) |
| "This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms." | 9.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| "This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life." | 9.12 | An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006) |
| "This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers." | 9.12 | Bupropion and cognitive-behavioral treatment for depression in smoking cessation. ( Abrams, D; Abrantes, AM; Brown, RA; Kahler, CW; Lloyd-Richardson, EE; Miller, IW; Niaura, R; Strong, DR, 2007) |
| "Bupropion SR treatment is an efficacious aid to smoking cessation in patients with COPD." | 9.11 | Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. ( Huibers, MJ; Knipschild, PG; van Schayck, CP; Wagena, EJ; Wouters, EF, 2005) |
| "The influence of depressive symptoms on smoking cessation was examined among 600 African American smokers who participated in a randomized, placebo-controlled trial of sustained-release bupropion hydrochloride." | 9.11 | The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. ( Ahluwalia, JS; Catley, D; Harris, KJ; Mayo, MS; Okuyemi, KS; Pankey, E, 2005) |
| "Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet." | 9.10 | Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002) |
| "The purpose of this study was to assess the analgesic potential of sustained-release (SR) bupropion for neuropathic pain." | 9.09 | Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. ( Davis, B; Semenchuk, MR, 2000) |
| "A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects." | 9.08 | A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997) |
| "The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy." | 8.82 | Review of bupropion for smoking cessation. ( Richmond, R; Zwar, N, 2003) |
| "Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking." | 8.81 | Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 8.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "Taken together, these results in rats suggest that rapid hypoglycemia can induce an anhedonic state characterized by impaired consummatory responses to nutritional incentive stimuli and that can be alleviated by the antidepressant bupropion." | 8.02 | Evidence of hypoglycemic anhedonia and modulation by bupropion in rats. ( Ayoub, S; Horman, T; Leri, F, 2021) |
| "The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression." | 7.91 | The effect of bupropion augmentation of minocycline in the treatment of depression. ( Addepalli, V; Bendale, M; DSouza, SR; Kale, PP, 2019) |
| "Bupropion is used for treatment of depression during pregnancy." | 7.83 | Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016) |
| "The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders." | 7.79 | Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013) |
| "This study assessed the effects of co-administration of bupropion with SSRIs: sertraline, paroxetine, citalopram, fluvoxamine, SNRIs: venlafaxine and milnacipran and NRI: desipramine, using an animal model of depression, the forced swimming test in mice." | 7.74 | Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? ( Bourin, M; Hascoet, M; Prica, C, 2008) |
| "A case of bupropion-induced constipation is reported." | 7.74 | Severe constipation associated with extended-release bupropion therapy. ( Green, CG; Lounsbery, JL; Medow, MA, 2008) |
| "To assess if certain personality factors (anxiety or depression) might predict the efficacy of bupropion for smoking cessation." | 7.71 | [Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy]. ( Carreras, JM; Coll, F; Lores, L; Quesada, M; Sampablo Lauro, I; Sánchez Agudo, L, 2002) |
| "To report a case of acute dystonia consisting of neck stiffness, trismus, and unilateral temporomandibular joint (TMJ) pain and subluxation secondary to an increase in sustained-release (SR) bupropion." | 7.71 | Bupropion-induced acute dystonia. ( Detweiler, MB; Harpold, GJ, 2002) |
| "Bupropion is a relatively new and popular medication with seizures as its major side effect." | 7.71 | Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. ( Avasarala, J; Pesola, GR, 2002) |
| "Bupropion was administered to a 45-year-old white man being treated for depression with psychosis." | 7.70 | Serum sickness induced by bupropion. ( Alao, AO; Armenta, WA; Yolles, JC, 1999) |
| "To describe the first incidence of eosinophilia following administration of bupropion." | 7.69 | Eosinophilia associated with bupropion. ( Housel, GJ; Mahowald, JA; Malesker, MA; Malone, PM; Soori, GS, 1995) |
| "Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases." | 6.71 | Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. ( Audrain-McGovern, J; Brown, RA; Epstein, LH; Hawk, LW; Lerman, C; Niaura, R; Patterson, F; Wileyto, EP, 2005) |
| "Bupropion SR was associated with dose-related weight loss in all 3 studies." | 6.69 | Safety profile of sustained-release bupropion in depression: results of three clinical trials. ( Ascher, JA; Batey, SR; Johnston, JA; Settle, EC; Stahl, SM, 1999) |
| "Mean bupropion t1/2 was 34." | 6.68 | Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ( Altieri, LP; DeVane, CL; Kirshner, M; Pollock, BG; Sweet, RA; Wright, B, 1995) |
| " Assessments of safety included vital signs, electrocardiogram, clinical laboratory tests, and adverse experiences." | 6.65 | Comparative efficacy and safety of bupropion and placebo in the treatment of depression. ( Brodie, HK; Fabre, L; Garver, D; McLendon, D; Zung, WW, 1983) |
| "Bupropion may be an alternative treatment for depression that does not include the sexual side effects associated with most of the prescribed antidepressants available; however, additional research is required." | 6.50 | Bupropion in the depression-related sexual dysfunction: a systematic review. ( Arias-Carrión, O; Machado, S; Nardi, AE; Pereira, VM; Silva, AC, 2014) |
| "In older adults with treatment-resistant depression, augmentation of existing antidepressants with aripiprazole improved well-being significantly more over 10 weeks than a switch to bupropion and was associated with a numerically higher incidence of remission." | 5.69 | Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. ( Blumberger, DM; Brown, PJ; Cristancho, P; Flint, AJ; Gebara, MA; Gettinger, TR; Karp, JF; Lavretsky, H; Lenard, E; Lenze, EJ; Miller, JP; Mulsant, BH; Nicol, GE; Oughli, HA; Pham, VT; Reynolds, CF; Rollman, BL; Roose, SP; Yang, L, 2023) |
| "Bupropion was considered as a good candidate for such systems due to high water solubility that requires frequent dosing." | 5.56 | Formulation, Characterization and Comparative Pharmacokinetic Study of Bupropion Floating Raft System as a Promising Approach for Treating Depression. ( Abdel Hamid, MM; El-Nabarawi, MA; Jasti, BR; Shoman, NA; Teaima, MH; Yasser, M, 2020) |
| " BAG was also not associated with a change in depression severity over time across both arms in the blinded phase or in the subsequent open-label bupropion phase." | 5.51 | Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression. ( Ahmed, R; Bermudez, C; Boyd, BD; Christman, S; Elson, D; Kang, H; Landman, BA; Ryan, C; Szymkowicz, SM; Taylor, WD, 2022) |
| "Bupropion was found to reduce the negative biases in emotional processing early in treatment, including a significant decrease in the percentage misclassification of other face emotions as sad and the number of negative self-referent words falsely recalled between baseline and week 2." | 5.48 | Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression. ( Browning, M; Drevets, WC; Furey, M; Harmer, CJ; Walsh, AEL, 2018) |
| "Drug effects on formalin-induced mechanical allodynia were evaluated for comparison." | 5.43 | Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. ( Leitl, MD; Negus, SS, 2016) |
| " The search terms included: "AXS-05" OR "dextromethorphan and bupropion" AND "depression"." | 5.41 | Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. ( Akbar, D; Cao, B; Ceban, F; Ho, R; Kwan, ATH; McIntyre, RS; Rhee, TG; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2023) |
| "Aripiprazole and bupropion were comparable in significantly lowering patients' QIDS SR16 scores and helping over 50% of the patients achieve remission." | 5.40 | Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. ( Crayton, J; Nasr, S; Popli, A; Wendt, B, 2014) |
| "The response frequency to mechanical allodynia in mice was measured with von Frey hairs." | 5.36 | Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010) |
| "The role of dopamine agonists in the treatment of depression is still being explored because of no sufficient number of controlled studies in this area." | 5.36 | Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. ( Durst, R; Raskin, S, 2010) |
| "A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue." | 5.34 | A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020) |
| "Bupropion has a unique mechanism of action: inhibition of the presynaptic reuptake of dopamine in addition to noradrenergic activity." | 5.31 | [Successful treatment of depression in a Parkinson disease patient with bupropion]. ( Leentjens, AF; Verhey, FR; Vreeling, FW, 2000) |
| "This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine." | 5.30 | The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019) |
| "In treatment of depression with less than optimal response, augmentation with either aripiprazole or bupropion was cost-effective relative to switching to bupropion." | 5.27 | Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. ( Johnson, GR; Mohamed, S; Park, A; Scrymgeour, A; Yoon, J; Zisook, S, 2018) |
| "Platelet derived growth factor, basic fibroblast growth factor, and granulocyte colony stimulating factor were measured as part of Bioplex Pro human cytokine 27-plex kit in participants of the Combining Medications to Enhance Depression Outcomes trial who provided baseline plasma (n=166) and were treated with either bupropion-plus-escitalopram, escitalopram-plus-placebo, or venlafaxine-plus-mirtazapine." | 5.24 | Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. ( Gadad, BS; Jha, MK; Minhajuddin, A; Trivedi, MH, 2017) |
| "Participants were weight-concerned women (n = 349) ages 18-65 enrolled in a randomized, double-blind, placebo-controlled smoking cessation trial of bupropion and cognitive behavioral therapy." | 5.20 | A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms? ( Cheng, Y; Creswell, KG; Levine, MD, 2015) |
| "While the combination therapy of varenicline and sustained release bupropion (bupropion SR) for cigarette smoking cessation can increase smoking abstinence rates, it has also been associated with increases in self-reported depressive symptoms." | 5.20 | Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. ( Ebbert, JO; Elrashidi, MY; Hong, AS; Schroeder, DR, 2015) |
| "The efficacy, safety, and tolerability of combined bupropion versus placebo using duloxetine as active reference drug, in patients with a DSM-IV diagnosis of major depression with atypical features and a history of treatment resistance, were evaluated in this preliminary six-week study." | 5.19 | Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. ( De Berardis, D; De Pasquale, C; Fornaro, M; Fornaro, P; Iasevoli, F; Martino, M; Mattei, C; Mungo, S; Prestia, D; Vinciguerra, V, 2014) |
| "To assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning." | 5.17 | Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. ( Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW, 2013) |
| "Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study." | 5.17 | Increase in work productivity of depressed individuals with improvement in depressive symptom severity. ( Balasubramani, GK; Daly, E; Gaynes, BN; Kurian, BT; Lesser, I; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR, 2013) |
| "Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers." | 5.16 | Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. ( Ahluwalia, JS; Benowitz, NL; Choi, WS; Cox, LS; Faseru, B; Mayo, MS; Nollen, NL; Okuyemi, KS; Tyndale, RF, 2012) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 5.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "Bupropion and cognitive-behavioral treatment (CBT) for depression have been used as components of treatments designed to alleviate affective disturbance during smoking cessation." | 5.14 | Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. ( Abrantes, AM; Brown, RA; Kahler, CW; Leventhal, AM; Lloyd-Richardson, E; Niaura, R; Strong, DR, 2009) |
| "This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms." | 5.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| "This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life." | 5.12 | An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006) |
| "This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers." | 5.12 | Bupropion and cognitive-behavioral treatment for depression in smoking cessation. ( Abrams, D; Abrantes, AM; Brown, RA; Kahler, CW; Lloyd-Richardson, EE; Miller, IW; Niaura, R; Strong, DR, 2007) |
| "Bupropion SR treatment is an efficacious aid to smoking cessation in patients with COPD." | 5.11 | Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. ( Huibers, MJ; Knipschild, PG; van Schayck, CP; Wagena, EJ; Wouters, EF, 2005) |
| "The influence of depressive symptoms on smoking cessation was examined among 600 African American smokers who participated in a randomized, placebo-controlled trial of sustained-release bupropion hydrochloride." | 5.11 | The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. ( Ahluwalia, JS; Catley, D; Harris, KJ; Mayo, MS; Okuyemi, KS; Pankey, E, 2005) |
| "Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet." | 5.10 | Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002) |
| "The purpose of this study was to assess the analgesic potential of sustained-release (SR) bupropion for neuropathic pain." | 5.09 | Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. ( Davis, B; Semenchuk, MR, 2000) |
| "A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects." | 5.08 | A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997) |
| "We obtained access to IPD from seven placebo-controlled trials comparing bupropion, duloxetine, escitalopram, mirtazapine, paroxetine or venlafaxine with placebo in the acute phase treatment of major depression (total n = 2803)." | 5.01 | Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. ( Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S, 2019) |
| " This paper reviews the prevalence of sexual dysfunction, weight gain and emotional detachment during SSRI treatment, the profile of bupropion for each of these events and the ability of bupropion to reverse them." | 4.84 | Review: Bupropion and SSRI-induced side effects. ( Demyttenaere, K; Jaspers, L, 2008) |
| "The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy." | 4.82 | Review of bupropion for smoking cessation. ( Richmond, R; Zwar, N, 2003) |
| "Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking." | 4.81 | Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 4.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "Taken together, these results in rats suggest that rapid hypoglycemia can induce an anhedonic state characterized by impaired consummatory responses to nutritional incentive stimuli and that can be alleviated by the antidepressant bupropion." | 4.02 | Evidence of hypoglycemic anhedonia and modulation by bupropion in rats. ( Ayoub, S; Horman, T; Leri, F, 2021) |
| "The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression." | 3.91 | The effect of bupropion augmentation of minocycline in the treatment of depression. ( Addepalli, V; Bendale, M; DSouza, SR; Kale, PP, 2019) |
| "Bupropion is used for treatment of depression during pregnancy." | 3.83 | Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016) |
| "Varenicline does not seem to be associated with an increased risk of documented cardiovascular events, depression, or self-harm when compared with NRT." | 3.81 | Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. ( Kotz, D; Sheikh, A; Simpson, C; van Schayck, OC; Viechtbauer, W; West, R, 2015) |
| "The dopamine reuptake inhibitor bupropion and dopamine D2/3 receptor agonist pramipexole have been clinically proven to improve both depression and treatment-resistant depression." | 3.80 | Effects of bupropion and pramipexole on cell proliferation in the hippocampus of adrenocorticotropic hormone-treated rats. ( Asanuma, M; Kitamura, Y; Kuwatsuka, K; Miyazaki, I; Onoue, Y; Sendo, T, 2014) |
| "The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders." | 3.79 | Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013) |
| "To compare the risk of suicide, self harm, and depression in patients prescribed varenicline or bupropion with those prescribed nicotine replacement therapy." | 3.79 | Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. ( Davies, NM; Gunnell, D; Martin, RM; Metcalfe, C; Thomas, KH; Windmeijer, F, 2013) |
| "We assessed the effects of acute administration of bupropion (a dopamine-norepinephrine reuptake inhibitor) on spontaneous locomotor activity and depression-like behaviour (using the forced-swim test)." | 3.78 | Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington's Disease with Dopaminergic Dysfunction. ( Argyropoulos, A; Hannan, AJ; Renoir, T, 2012) |
| "Overall we identified 3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement." | 3.77 | Suicidal behavior and depression in smoking cessation treatments. ( Furberg, CD; Glenmullen, J; Maltsberger, JT; Moore, TJ; Singh, S, 2011) |
| "The dopamine reuptake inhibitor bupropion has clinically been proven to improve depression and treatment-resistant depression." | 3.76 | Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. ( Asanuma, M; Gomita, Y; Kawasaki, H; Kitagawa, K; Kitamura, Y; Shinomiya, K; Yagi, T, 2010) |
| "This study assessed the effects of co-administration of bupropion with SSRIs: sertraline, paroxetine, citalopram, fluvoxamine, SNRIs: venlafaxine and milnacipran and NRI: desipramine, using an animal model of depression, the forced swimming test in mice." | 3.74 | Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? ( Bourin, M; Hascoet, M; Prica, C, 2008) |
| "A case of bupropion-induced constipation is reported." | 3.74 | Severe constipation associated with extended-release bupropion therapy. ( Green, CG; Lounsbery, JL; Medow, MA, 2008) |
| "Chronic nicotine infusion reduces the synthesis of 5HTT protein, which may consequently precipitate depression during nicotine withdrawal, but co-administration of bupropion may ameliorate withdrawal symptoms by counteracting nicotine's effect on 5HTT." | 3.74 | Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion. ( Semba, J; Wakuta, M, 2008) |
| " One month prior to her skin outbreak she was started on bupropion for mild depression." | 3.73 | Bupropion-induced subacute cutaneous lupus erythematosus. ( Callen, JP; Cassis, TB, 2005) |
| "To report a case of acute dystonia consisting of neck stiffness, trismus, and unilateral temporomandibular joint (TMJ) pain and subluxation secondary to an increase in sustained-release (SR) bupropion." | 3.71 | Bupropion-induced acute dystonia. ( Detweiler, MB; Harpold, GJ, 2002) |
| "Bupropion is a relatively new and popular medication with seizures as its major side effect." | 3.71 | Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. ( Avasarala, J; Pesola, GR, 2002) |
| "Bupropion was administered to a 45-year-old white man being treated for depression with psychosis." | 3.70 | Serum sickness induced by bupropion. ( Alao, AO; Armenta, WA; Yolles, JC, 1999) |
| "To describe the first incidence of eosinophilia following administration of bupropion." | 3.69 | Eosinophilia associated with bupropion. ( Housel, GJ; Mahowald, JA; Malesker, MA; Malone, PM; Soori, GS, 1995) |
| "Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied." | 3.30 | Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. ( Ahn, YM; Arumugham, SS; Ashok, MV; Beaulieu, S; Bhandary, RP; Bond, DJ; Daigneault, A; Frey, BN; Ha, K; Kesavan, M; Kondapuram, N; Lam, RW; Milev, R; Murthy, NS; Ouyang, Y; Ramachandran, K; Ravindran, A; Ravindran, N; Reddy, MS; Reddy, YCJ; Saraf, G; Schaffer, A; Wong, H; Yatham, LN, 2023) |
| "Bupropion combinations were not superior to monotherapy (SMD = 0." | 2.82 | Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. ( Alexander, D; Baethge, C; Bschor, T; Henssler, J; Schwarzer, G, 2022) |
| "Bupropion pre-treatment had no statistically significant effect on the innate immune response to LPS or on LPS-induced behavioral changes, suggesting that 1-week pre-treatment with bupropion does not inhibit LPS-induced fatigue and anhedonia, contrary to what was found previously with citalopram." | 2.78 | Bupropion pre-treatment of endotoxin-induced depressive symptoms. ( DellaGioia, N; Devine, L; Hannestad, J; Pittman, B, 2013) |
| "Few studies have examined whether nicotine dependence self-report questionnaires can predict specific behaviors and symptoms at specific points in time." | 2.74 | Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures. ( Baker, TB; Bolt, DM; Japuntich, SJ; Piper, ME; Schlam, TR, 2009) |
| " Previous cost-effectiveness analyses have not fully accounted for adverse effects nor compared all cessation aids." | 2.72 | Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events. ( Caldwell, DM; Dalili, MN; Keeney, E; López-López, JA; Munafò, MR; Phillippo, DM; Stevenson, M; Thomas, KH; Welton, NJ, 2021) |
| "Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases." | 2.71 | Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. ( Audrain-McGovern, J; Brown, RA; Epstein, LH; Hawk, LW; Lerman, C; Niaura, R; Patterson, F; Wileyto, EP, 2005) |
| "When considering treating perinatal depression with a drug indicated for the treatment of depression, the major concerns are whether the drug increases the risks of teratogenicity, pregnancy complications, poor neonatal adaptation, or neurodevelopmental disorders." | 2.58 | Pharmacotherapy for Perinatal Depression. ( Albertini, ES; Ernst, C; Fersh, ME; Habib, S; Khan, SJ; Lusskin, SI, 2018) |
| "To assess the risk of headache associated with commonly prescribed antidepressant medications and to examine the impact of medication class, pharmacodynamics and dosage on risk of headache." | 2.58 | Meta-analysis: Second generation antidepressants and headache. ( Bloch, MH; Olten, B; Telang, S; Walton, C, 2018) |
| "Buspirone has an indication for generalized anxiety disorder though studies show only a minimal benefit." | 2.53 | Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. ( Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016) |
| "Bupropion may be an alternative treatment for depression that does not include the sexual side effects associated with most of the prescribed antidepressants available; however, additional research is required." | 2.50 | Bupropion in the depression-related sexual dysfunction: a systematic review. ( Arias-Carrión, O; Machado, S; Nardi, AE; Pereira, VM; Silva, AC, 2014) |
| "Preferred drugs for treating depression in epilepsy are serotonin reuptake inhibitors." | 2.49 | [Antidepressants in epilepsy]. ( Castaño-Monsalve, B, 2013) |
| "Psoriasis is a common condition, affecting 1." | 2.42 | Psychiatric morbidity in psoriasis: a review. ( Cooper, AJ; Ilchef, R; Russo, PA, 2004) |
| "Selegiline is a selective monoamine oxidase inhibitor used in the treatment of Parkinson's disease." | 2.40 | Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. ( Alexander, B; Ritter, JL, 1997) |
| " We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons." | 1.51 | Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice. ( Ishibashi, T; Iwadate, R; Kawai, H; Kawashima, Y; Kudo, N; Mitsumoto, A, 2019) |
| "Bupropion was found to reduce the negative biases in emotional processing early in treatment, including a significant decrease in the percentage misclassification of other face emotions as sad and the number of negative self-referent words falsely recalled between baseline and week 2." | 1.48 | Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression. ( Browning, M; Drevets, WC; Furey, M; Harmer, CJ; Walsh, AEL, 2018) |
| "Drug effects on formalin-induced mechanical allodynia were evaluated for comparison." | 1.43 | Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. ( Leitl, MD; Negus, SS, 2016) |
| "Aripiprazole and bupropion were comparable in significantly lowering patients' QIDS SR16 scores and helping over 50% of the patients achieve remission." | 1.40 | Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. ( Crayton, J; Nasr, S; Popli, A; Wendt, B, 2014) |
| "Depression is the leading psychiatric disorder with a high risk of morbidity and mortality." | 1.40 | Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice. ( Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W, 2014) |
| "Fatigue is a common symptom in individuals with multiple sclerosis (MS)." | 1.39 | Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013) |
| " When managing a patient with nonpsychotic depression and inadequate response to the maximum dose of a single antidepressant, the physician should first identify factors that may contribute to the poor response, such as suboptimal dosage resulting from nonadherence, inadequate duration of therapy, and comorbid medical and psychiatric conditions." | 1.36 | Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant? ( Lo, V; Maggio, L, 2010) |
| "The response frequency to mechanical allodynia in mice was measured with von Frey hairs." | 1.36 | Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010) |
| "The role of dopamine agonists in the treatment of depression is still being explored because of no sufficient number of controlled studies in this area." | 1.36 | Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. ( Durst, R; Raskin, S, 2010) |
| "Bupropion has a unique mechanism of action: inhibition of the presynaptic reuptake of dopamine in addition to noradrenergic activity." | 1.31 | [Successful treatment of depression in a Parkinson disease patient with bupropion]. ( Leentjens, AF; Verhey, FR; Vreeling, FW, 2000) |
| "Bupropion is a novel antidepressant, distinct from tricyclic antidepressants both neurochemically and behaviorally." | 1.28 | Antidepressant profile of bupropion and three metabolites in mice. ( Colin, JN; Lacomblez, L; Martin, P; Massol, J; Puech, AJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (5.92) | 18.7374 |
| 1990's | 11 (7.24) | 18.2507 |
| 2000's | 49 (32.24) | 29.6817 |
| 2010's | 58 (38.16) | 24.3611 |
| 2020's | 25 (16.45) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, LF | 1 |
| Zhang, HK | 1 |
| Caldarone, BJ | 1 |
| Eaton, JB | 1 |
| Lukas, RJ | 1 |
| Kozikowski, AP | 1 |
| Ahmed, R | 3 |
| Ryan, C | 1 |
| Christman, S | 1 |
| Elson, D | 3 |
| Bermudez, C | 1 |
| Landman, BA | 3 |
| Szymkowicz, SM | 3 |
| Boyd, BD | 3 |
| Kang, H | 3 |
| Taylor, WD | 3 |
| Henssler, J | 1 |
| Alexander, D | 1 |
| Schwarzer, G | 1 |
| Bschor, T | 1 |
| Baethge, C | 1 |
| Cinciripini, PM | 2 |
| Kypriotakis, G | 1 |
| Green, C | 1 |
| Lawrence, D | 1 |
| Anthenelli, RM | 1 |
| Minnix, J | 1 |
| Blalock, JA | 1 |
| Beneventi, D | 1 |
| Morris, C | 1 |
| Karam-Hage, M | 2 |
| Schwalsberger, K | 1 |
| Reininghaus, B | 1 |
| Reiter, A | 1 |
| Dalkner, N | 1 |
| Fleischmann, E | 1 |
| Fellendorf, F | 1 |
| Platzer, M | 1 |
| Reininghaus, EZ | 1 |
| Cook, J | 1 |
| Halaris, A | 1 |
| Peters, EM | 1 |
| Balbuena, L | 1 |
| Lodhi, RJ | 1 |
| Chaki, S | 3 |
| Watanabe, M | 3 |
| Albert, K | 2 |
| Begnoche, P | 2 |
| Andrews, P | 2 |
| Vega, J | 2 |
| Zhang, H | 2 |
| Gilbert, E | 2 |
| Hussain, S | 2 |
| Veldhuizen, S | 2 |
| Le Foll, B | 2 |
| Selby, P | 3 |
| Zawertailo, L | 2 |
| Lenze, EJ | 1 |
| Mulsant, BH | 1 |
| Roose, SP | 1 |
| Lavretsky, H | 1 |
| Reynolds, CF | 1 |
| Blumberger, DM | 1 |
| Brown, PJ | 1 |
| Cristancho, P | 1 |
| Flint, AJ | 1 |
| Gebara, MA | 1 |
| Gettinger, TR | 1 |
| Lenard, E | 1 |
| Miller, JP | 1 |
| Nicol, GE | 1 |
| Oughli, HA | 1 |
| Pham, VT | 1 |
| Rollman, BL | 1 |
| Yang, L | 1 |
| Karp, JF | 1 |
| Yatham, LN | 1 |
| Arumugham, SS | 1 |
| Kesavan, M | 1 |
| Ramachandran, K | 1 |
| Murthy, NS | 1 |
| Saraf, G | 1 |
| Ouyang, Y | 1 |
| Bond, DJ | 1 |
| Schaffer, A | 1 |
| Ravindran, A | 1 |
| Ravindran, N | 1 |
| Frey, BN | 1 |
| Daigneault, A | 1 |
| Beaulieu, S | 1 |
| Lam, RW | 1 |
| Kondapuram, N | 1 |
| Reddy, MS | 1 |
| Bhandary, RP | 1 |
| Ashok, MV | 1 |
| Ha, K | 1 |
| Ahn, YM | 1 |
| Milev, R | 1 |
| Wong, H | 1 |
| Reddy, YCJ | 1 |
| Blaszczyk, AT | 1 |
| Mathys, M | 1 |
| Le, J | 1 |
| Ebell, MH | 1 |
| Akbar, D | 1 |
| Rhee, TG | 1 |
| Ceban, F | 1 |
| Ho, R | 1 |
| Teopiz, KM | 1 |
| Cao, B | 1 |
| Subramaniapillai, M | 1 |
| Kwan, ATH | 1 |
| Rosenblat, JD | 1 |
| McIntyre, RS | 1 |
| Kurogi, K | 1 |
| Taniguchi, F | 1 |
| Matsuo, R | 1 |
| Shinozuka, M | 1 |
| Suzaki, R | 1 |
| Yasuo, S | 1 |
| Jim, HSL | 1 |
| Hoogland, AI | 1 |
| Han, HS | 1 |
| Culakova, E | 1 |
| Heckler, C | 1 |
| Janelsins, M | 1 |
| Williams, GC | 1 |
| Bower, J | 1 |
| Cole, S | 1 |
| Desta, Z | 1 |
| Babilonia, MB | 1 |
| Morrow, G | 1 |
| Peppone, L | 1 |
| de la Salle, S | 1 |
| Jaworska, N | 2 |
| Blier, P | 3 |
| Smith, D | 1 |
| Knott, V | 2 |
| Puri, S | 1 |
| Coplan, BM | 1 |
| McGuire, PR | 1 |
| Teaima, MH | 1 |
| Abdel Hamid, MM | 1 |
| Shoman, NA | 1 |
| Jasti, BR | 1 |
| El-Nabarawi, MA | 1 |
| Yasser, M | 1 |
| de Almeida, GRL | 1 |
| Szczepanik, JC | 1 |
| Selhorst, I | 1 |
| Schmitz, AE | 1 |
| Dos Santos, B | 1 |
| Cunha, MP | 1 |
| Heinrich, IA | 1 |
| de Paula, GC | 1 |
| De Bem, AF | 1 |
| Leal, RB | 1 |
| Dafre, AL | 1 |
| Cândido, RCF | 1 |
| Menezes de Padua, CA | 1 |
| Golder, S | 1 |
| Junqueira, DR | 1 |
| Horman, T | 1 |
| Ayoub, S | 1 |
| Leri, F | 1 |
| Keeney, E | 1 |
| Welton, NJ | 1 |
| Stevenson, M | 1 |
| Dalili, MN | 1 |
| López-López, JA | 1 |
| Caldwell, DM | 1 |
| Phillippo, DM | 1 |
| Munafò, MR | 1 |
| Thomas, KH | 3 |
| Sathe, AR | 1 |
| Thiemann, A | 1 |
| Toulouie, S | 1 |
| Durant, E | 1 |
| Jha, MK | 2 |
| Minhajuddin, A | 2 |
| Gadad, BS | 1 |
| Trivedi, MH | 5 |
| Secades-Villa, R | 1 |
| González-Roz, A | 1 |
| García-Pérez, Á | 1 |
| Becoña, E | 1 |
| Walsh, AEL | 1 |
| Browning, M | 1 |
| Drevets, WC | 1 |
| Furey, M | 1 |
| Harmer, CJ | 1 |
| Wakhlu, S | 1 |
| Dronamraju, N | 1 |
| Greer, TL | 1 |
| Lusskin, SI | 1 |
| Khan, SJ | 1 |
| Ernst, C | 1 |
| Habib, S | 1 |
| Fersh, ME | 1 |
| Albertini, ES | 1 |
| Telang, S | 1 |
| Walton, C | 1 |
| Olten, B | 1 |
| Bloch, MH | 1 |
| Kim, EJ | 1 |
| Felsovalyi, K | 1 |
| Young, LM | 1 |
| Shmelkov, SV | 1 |
| Grunebaum, MF | 1 |
| Cardozo, T | 1 |
| De La Garza, N | 1 |
| Rush, AJ | 3 |
| Killian, MO | 1 |
| Grannemann, BD | 1 |
| Carmody, TJ | 1 |
| Frizzell, W | 1 |
| Howard, L | 1 |
| Norris, HC | 1 |
| Chien, J | 1 |
| Yoon, J | 1 |
| Zisook, S | 1 |
| Park, A | 1 |
| Johnson, GR | 1 |
| Scrymgeour, A | 1 |
| Mohamed, S | 1 |
| Noma, H | 1 |
| Furukawa, TA | 1 |
| Maruo, K | 1 |
| Imai, H | 1 |
| Shinohara, K | 1 |
| Tanaka, S | 1 |
| Ikeda, K | 1 |
| Yamawaki, S | 1 |
| Cipriani, A | 1 |
| Kawai, H | 1 |
| Iwadate, R | 1 |
| Ishibashi, T | 1 |
| Kudo, N | 1 |
| Kawashima, Y | 1 |
| Mitsumoto, A | 1 |
| Bendale, M | 1 |
| DSouza, SR | 1 |
| Addepalli, V | 1 |
| Kale, PP | 1 |
| Robinson, JD | 1 |
| Minnix, JA | 1 |
| Lam, C | 1 |
| Versace, F | 1 |
| Brown, VL | 1 |
| Engelmann, JM | 1 |
| Wetter, DW | 1 |
| Morris, DW | 2 |
| Wisniewski, SR | 2 |
| Lesser, I | 1 |
| Nierenberg, AA | 2 |
| Daly, E | 1 |
| Kurian, BT | 2 |
| Gaynes, BN | 1 |
| Balasubramani, GK | 1 |
| Castaño-Monsalve, B | 1 |
| Hays, JT | 1 |
| Gibbons, RD | 1 |
| Mann, JJ | 1 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 1 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Maciel, IS | 1 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 1 |
| Campos, MM | 1 |
| Martin, RM | 2 |
| Davies, NM | 2 |
| Metcalfe, C | 2 |
| Windmeijer, F | 2 |
| Gunnell, D | 2 |
| Davies, SP | 1 |
| Nunes, EJ | 2 |
| Randall, PA | 2 |
| Hart, EE | 1 |
| Freeland, C | 1 |
| Yohn, SE | 2 |
| Baqi, Y | 2 |
| Müller, CE | 2 |
| López-Cruz, L | 1 |
| Correa, M | 2 |
| Salamone, JD | 2 |
| Onoue, Y | 1 |
| Kuwatsuka, K | 1 |
| Miyazaki, I | 1 |
| Asanuma, M | 2 |
| Kitamura, Y | 2 |
| Sendo, T | 1 |
| Blondeau, C | 1 |
| Tessier, P | 1 |
| Norris, S | 1 |
| Fusee, W | 1 |
| Nasr, S | 1 |
| Wendt, B | 1 |
| Popli, A | 1 |
| Crayton, J | 1 |
| Fornaro, M | 1 |
| Martino, M | 1 |
| Mattei, C | 1 |
| Prestia, D | 1 |
| Vinciguerra, V | 1 |
| De Berardis, D | 1 |
| De Pasquale, C | 1 |
| Iasevoli, F | 1 |
| Mungo, S | 1 |
| Fornaro, P | 1 |
| Pereira, VM | 1 |
| Arias-Carrión, O | 1 |
| Machado, S | 1 |
| Nardi, AE | 1 |
| Silva, AC | 1 |
| Lee, CA | 1 |
| Nowak, V | 1 |
| Khan, B | 1 |
| Shah, P | 1 |
| Pandit, S | 1 |
| Vemuri, VK | 1 |
| Makriyannis, A | 1 |
| Renoir, T | 1 |
| Argyropoulos, A | 1 |
| Hannan, AJ | 1 |
| Creswell, KG | 1 |
| Cheng, Y | 1 |
| Levine, MD | 1 |
| Mlyniec, K | 1 |
| Ostachowicz, B | 1 |
| Krakowska, A | 1 |
| Reczynski, W | 1 |
| Opoka, W | 1 |
| Nowak, G | 1 |
| Hong, AS | 1 |
| Elrashidi, MY | 1 |
| Schroeder, DR | 2 |
| Ebbert, JO | 1 |
| Weissman, MM | 1 |
| Wickramaratne, P | 1 |
| Pilowsky, DJ | 1 |
| Poh, E | 1 |
| Batten, LA | 1 |
| Hernandez, M | 1 |
| Flament, MF | 1 |
| Stewart, JA | 1 |
| McGrath, P | 1 |
| Stewart, JW | 2 |
| Coiro, MJ | 1 |
| Kotz, D | 1 |
| Viechtbauer, W | 1 |
| Simpson, C | 1 |
| van Schayck, OC | 1 |
| West, R | 1 |
| Sheikh, A | 1 |
| Roni, MA | 1 |
| Rahman, S | 1 |
| Leitl, MD | 1 |
| Negus, SS | 1 |
| Thorkelson, G | 1 |
| Bielefeldt, K | 1 |
| Szigethy, E | 1 |
| Fokina, VM | 1 |
| West, H | 1 |
| Oncken, C | 1 |
| Clark, SM | 1 |
| Ahmed, MS | 1 |
| Hankins, GD | 1 |
| Nanovskaya, TN | 1 |
| Jiménez Ruiz, CA | 1 |
| Riesco Miranda, JA | 1 |
| Roopan, S | 1 |
| Larsen, ER | 1 |
| Prica, C | 1 |
| Hascoet, M | 2 |
| Bourin, M | 2 |
| Lounsbery, JL | 1 |
| Medow, MA | 1 |
| Green, CG | 1 |
| Semba, J | 1 |
| Wakuta, M | 1 |
| Iñiguez, SD | 1 |
| Warren, BL | 1 |
| Parise, EM | 1 |
| Alcantara, LF | 1 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Bolaños-Guzmán, CA | 1 |
| Arias, HR | 1 |
| Strong, DR | 2 |
| Kahler, CW | 2 |
| Leventhal, AM | 1 |
| Abrantes, AM | 2 |
| Lloyd-Richardson, E | 1 |
| Niaura, R | 3 |
| Brown, RA | 3 |
| Lebovits, A | 1 |
| Hainline, B | 1 |
| Stone, LS | 1 |
| Seminowicz, DA | 1 |
| Brunz, JT | 1 |
| Rosenquist, RW | 1 |
| Cowan, P | 1 |
| Japuntich, SJ | 1 |
| Piper, ME | 1 |
| Schlam, TR | 1 |
| Bolt, DM | 1 |
| Baker, TB | 2 |
| Schnoll, RA | 1 |
| Martinez, E | 1 |
| Tatum, KL | 1 |
| Weber, DM | 1 |
| Kuzla, N | 1 |
| Glass, M | 1 |
| Ridge, JA | 1 |
| Langer, C | 1 |
| Miyamoto, C | 1 |
| Wileyto, EP | 2 |
| Leone, F | 1 |
| Englisch, S | 1 |
| Esser, A | 1 |
| Zink, M | 1 |
| Lo, V | 1 |
| Maggio, L | 1 |
| Bares, M | 1 |
| Brunovsky, M | 1 |
| Novak, T | 1 |
| Kopecek, M | 1 |
| Stopkova, P | 1 |
| Sos, P | 1 |
| Krajca, V | 1 |
| Höschl, C | 1 |
| Yagi, T | 1 |
| Kitagawa, K | 1 |
| Shinomiya, K | 1 |
| Kawasaki, H | 2 |
| Gomita, Y | 1 |
| Jesse, CR | 1 |
| Wilhelm, EA | 1 |
| Nogueira, CW | 1 |
| Raskin, S | 1 |
| Durst, R | 1 |
| Bobo, WV | 1 |
| Chen, H | 1 |
| Fava, M | 1 |
| Warden, D | 1 |
| Luther, JF | 1 |
| Husain, MM | 1 |
| Cook, IA | 1 |
| Lesser, IM | 1 |
| Kornstein, SG | 1 |
| Shelton, RC | 2 |
| Takechi, K | 1 |
| Suemaru, K | 1 |
| Araki, H | 1 |
| Moore, TJ | 1 |
| Furberg, CD | 1 |
| Glenmullen, J | 1 |
| Maltsberger, JT | 1 |
| Singh, S | 1 |
| Cox, LS | 1 |
| Nollen, NL | 1 |
| Mayo, MS | 2 |
| Choi, WS | 1 |
| Faseru, B | 1 |
| Benowitz, NL | 1 |
| Tyndale, RF | 1 |
| Okuyemi, KS | 2 |
| Ahluwalia, JS | 2 |
| Lung, D | 1 |
| Yeh, K | 1 |
| Kiang, C | 1 |
| Pardini, M | 1 |
| Capello, E | 1 |
| Krueger, F | 1 |
| Mancardi, G | 1 |
| Uccelli, A | 1 |
| DellaGioia, N | 1 |
| Devine, L | 1 |
| Pittman, B | 1 |
| Hannestad, J | 1 |
| Tonstad, S | 1 |
| Sampablo Lauro, I | 1 |
| Carreras, JM | 1 |
| Lores, L | 1 |
| Quesada, M | 1 |
| Coll, F | 1 |
| Sánchez Agudo, L | 1 |
| Jain, AK | 1 |
| Kaplan, RA | 1 |
| Gadde, KM | 1 |
| Wadden, TA | 1 |
| Allison, DB | 1 |
| Brewer, ER | 1 |
| Leadbetter, RA | 1 |
| Richard, N | 1 |
| Haight, B | 1 |
| Jamerson, BD | 1 |
| Buaron, KS | 1 |
| Metz, A | 1 |
| Smith, SS | 1 |
| Jorenby, DE | 1 |
| Leischow, SJ | 1 |
| Nides, MA | 1 |
| Rennard, SI | 1 |
| Johnston, JA | 3 |
| Jamerson, B | 1 |
| Fiore, MC | 1 |
| Richmond, R | 1 |
| Zwar, N | 1 |
| Ripoll, N | 1 |
| David, DJ | 1 |
| Dailly, E | 1 |
| Tomarken, AJ | 1 |
| Dichter, GS | 1 |
| Freid, C | 1 |
| Addington, S | 1 |
| Fakhfakh, R | 1 |
| Hsairi, M | 1 |
| Gharbi, L | 1 |
| Aouina, H | 1 |
| Bouacha, H | 1 |
| Achour, N | 1 |
| Wax, CM | 1 |
| Russo, PA | 1 |
| Ilchef, R | 1 |
| Cooper, AJ | 1 |
| Prochaska, JJ | 2 |
| Rossi, JS | 2 |
| Redding, CA | 2 |
| Rosen, AB | 2 |
| Tsoh, JY | 2 |
| Humfleet, GL | 1 |
| Eisendrath, SJ | 1 |
| Meisner, MR | 1 |
| Hall, SM | 2 |
| Yamada, J | 1 |
| Sugimoto, Y | 1 |
| Yamada, S | 1 |
| Haug, NA | 1 |
| Humfleet, G | 1 |
| Delucchi, K | 1 |
| Eisendrath, S | 1 |
| Patterson, F | 1 |
| Epstein, LH | 1 |
| Audrain-McGovern, J | 1 |
| Hawk, LW | 1 |
| Lerman, C | 1 |
| Moss, EL | 1 |
| Simpson, JS | 1 |
| Pelletier, G | 1 |
| Forsyth, P | 1 |
| Cassis, TB | 1 |
| Callen, JP | 1 |
| Wagena, EJ | 1 |
| Knipschild, PG | 1 |
| Huibers, MJ | 1 |
| Wouters, EF | 1 |
| van Schayck, CP | 1 |
| Catley, D | 1 |
| Harris, KJ | 1 |
| Pankey, E | 1 |
| Dobkin, RD | 1 |
| Menza, M | 1 |
| Marin, H | 1 |
| Allen, LA | 1 |
| Rousso, R | 1 |
| Leiblum, SR | 1 |
| Basson, R | 1 |
| Brotto, LA | 1 |
| Laan, E | 1 |
| Redmond, G | 1 |
| Utian, WH | 1 |
| McCreadie, R | 1 |
| Chan, CH | 1 |
| Liu, HC | 1 |
| Huang, MC | 1 |
| Padala, PR | 1 |
| Madaan, V | 1 |
| Sattar, SP | 1 |
| Dhir, A | 1 |
| Kulkarni, SK | 1 |
| Grandas, F | 1 |
| López-Manzanares, L | 1 |
| Lloyd-Richardson, EE | 1 |
| Abrams, D | 1 |
| Miller, IW | 1 |
| Moura, MA | 1 |
| Dattilo, PB | 1 |
| Nordin, C | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Demyttenaere, K | 1 |
| Jaspers, L | 1 |
| Zung, WW | 1 |
| Brodie, HK | 1 |
| Fabre, L | 1 |
| McLendon, D | 1 |
| Garver, D | 1 |
| Ajac, IK | 1 |
| Giroux, LJ | 1 |
| Hill, JA | 1 |
| Cooper, TB | 1 |
| Suckow, RF | 1 |
| Glassman, A | 1 |
| Hughes, S | 1 |
| Barnett, S | 1 |
| Sosnouski, P | 1 |
| Kirksey, DF | 1 |
| Fogel, P | 1 |
| Mamer, OA | 1 |
| Chouinard, G | 2 |
| Farrell, PG | 1 |
| Stern, WC | 1 |
| Harto-Truax, N | 1 |
| Annable, L | 1 |
| Langlois, R | 1 |
| Briggs, GG | 1 |
| Samson, JH | 1 |
| Ambrose, PJ | 1 |
| Schroeder, DH | 1 |
| Malesker, MA | 1 |
| Soori, GS | 1 |
| Malone, PM | 1 |
| Mahowald, JA | 1 |
| Housel, GJ | 1 |
| Sweet, RA | 1 |
| Pollock, BG | 1 |
| Kirshner, M | 1 |
| Wright, B | 1 |
| Altieri, LP | 1 |
| DeVane, CL | 1 |
| Ritter, JL | 1 |
| Alexander, B | 1 |
| Hurt, RD | 1 |
| Sachs, DP | 1 |
| Glover, ED | 1 |
| Offord, KP | 1 |
| Dale, LC | 1 |
| Khayrallah, MA | 1 |
| Glover, PN | 1 |
| Sullivan, CR | 1 |
| Croghan, IT | 1 |
| Sullivan, PM | 1 |
| Settle, EC | 1 |
| Stahl, SM | 1 |
| Batey, SR | 1 |
| Ascher, JA | 1 |
| Yolles, JC | 1 |
| Armenta, WA | 1 |
| Alao, AO | 1 |
| Semenchuk, MR | 1 |
| Davis, B | 1 |
| Weintraub, D | 1 |
| Linder, MW | 1 |
| Leentjens, AF | 1 |
| Verhey, FR | 1 |
| Vreeling, FW | 1 |
| Detweiler, MB | 1 |
| Harpold, GJ | 1 |
| Pesola, GR | 1 |
| Avasarala, J | 1 |
| Sullivan, MA | 1 |
| Covey, LS | 1 |
| Cohen, LJ | 1 |
| Grothe, DR | 1 |
| Harsch, HH | 1 |
| Feinberg, M | 1 |
| Martin, P | 1 |
| Massol, J | 1 |
| Colin, JN | 1 |
| Lacomblez, L | 1 |
| Puech, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With[NCT01456936] | Phase 4 | 8,144 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood[NCT00550667] | 1,120 participants (Actual) | Observational | 2007-10-01 | Completed | |||
| Smoking Cessation Treatment for Substance Use Dependents[NCT03551704] | 120 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | |||
| A Randomised Controlled Trial Evaluating the Efficacy and Mechanisms of a Ketogenic Diet as an Adjunctive Treatment for People With Treatment-resistant Depression[NCT06091163] | 100 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)[NCT01421342] | Phase 3 | 1,522 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Pharmacogenetics, Emotional Reactivity and Smoking[NCT00507728] | Phase 2/Phase 3 | 646 participants (Actual) | Interventional | 2005-12-08 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| [NCT02681848] | 180,000 participants (Anticipated) | Observational | 2006-09-01 | Active, not recruiting | |||
| Combining Antidepressants to Hasten Remission From Depression[NCT00519428] | Phase 4 | 245 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.[NCT01930422] | 34 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Tobacco Treatment for Employable Californians (TTEC), Improving Employability Partnership: Alliance to Curb Tobacco (Total IMPACT)[NCT02478697] | 360 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Bio-behavioral Lung Cancer Prevention Program[NCT00322205] | Phase 4 | 555 participants | Interventional | 1999-06-30 | Completed | ||
| Telemedicine for Smoking Cessation in Rural Primary Care[NCT00843505] | Phase 3 | 566 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| High Dose Bupropion Treatment for Smoking Cessation - Pilot Study[NCT03326128] | Phase 2 | 12 participants (Actual) | Interventional | 2021-09-01 | Terminated (stopped due to Due to the COVID-19 pandemic, it was difficult to recruit eligible participants.) | ||
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321] | Phase 2 | 522 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population[NCT01015170] | Phase 4 | 454 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 33.5 |
| Bupropion 150 mg BID | 22.6 |
| NRT Patch | 23.4 |
| Placebo | 12.5 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 38.0 |
| Bupropion 150 mg BID | 26.1 |
| NRT Patch | 26.4 |
| Placebo | 13.7 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 29.2 |
| Bupropion 150 mg BID | 19.3 |
| NRT Patch | 20.4 |
| Placebo | 11.4 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 21.8 |
| Bupropion 150 mg BID | 16.2 |
| NRT Patch | 15.7 |
| Placebo | 9.4 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 25.5 |
| Bupropion 150 mg BID | 18.8 |
| NRT Patch | 18.5 |
| Placebo | 10.5 |
"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Varenicline 1.0 mg BID | 18.3 |
| Bupropion 150 mg BID | 13.7 |
| NRT Patch | 13.0 |
| Placebo | 8.3 |
"The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as normal, not at all ill on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as no change on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs." (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | percentage of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 1986, 1974, 1986, 1982) | Week 2 (N= 1934, 1936, 1927, 1926) | Week 3 (N= 1880, 1892, 1880, 1863) | Week 4 (N= 1860, 1856, 1858, 1834) | Week 5 (N= 1828, 1816, 1822, 1802) | Week 6 (N= 1816, 1808, 1820, 1773) | Week 8 (N= 1758, 1756, 1755, 1738) | Week 10 (N= 1717, 1707, 1715, 1675) | Week 12 (N= 1558, 1572, 1540, 1492) | Week 13 (N= 1612, 16081602, 1575) | Week 16 (N= 1586, 1606, 1568, 1541) | Week 20 (N= 1563, 1573, 1523, 1510) | Week 24 (N= 1533, 1515, 1499, 1497) | |
| Bupropion 150 mg BID | 93.2 | 90.8 | 89.8 | 88.0 | 86.5 | 86.5 | 83.6 | 81.7 | 75.1 | 76.7 | 76.7 | 75.0 | 72.3 |
| NRT Patch | 94.6 | 90.5 | 88.7 | 87.1 | 85.5 | 85.1 | 82.8 | 80.4 | 72.2 | 75.2 | 73.9 | 72.2 | 71.1 |
| Placebo | 95.1 | 91.2 | 87.9 | 86.3 | 85.4 | 84.1 | 81.9 | 79.2 | 71.3 | 74.9 | 73.4 | 71.7 | 71.1 |
| Varenicline 1.0 mg BID | 94.2 | 90.8 | 88.3 | 86.6 | 85.7 | 85.2 | 82.4 | 80.6 | 72.9 | 75.9 | 74.2 | 73.4 | 71.8 |
"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | |
| Bupropion 150 mg BID | 1.1 | 17.9 | 22.3 | 24.4 | 25.7 | 26.9 | 30.2 | 26.5 | 30.4 | 27.6 | 30.7 | 27.1 | 26.5 | 29.2 | 29.2 | 25.1 | 27.9 | 27.8 | 27.9 | 23.9 | 26.7 | 26.4 | 27.0 | 23.2 |
| NRT Patch | 0.9 | 14.2 | 20.0 | 23.5 | 25.1 | 26.8 | 31.3 | 28.0 | 32.1 | 28.0 | 32.1 | 27.6 | 26.9 | 29.4 | 29.2 | 24.9 | 28.1 | 28.2 | 28.1 | 23.7 | 26.5 | 26.3 | 25.3 | 23.6 |
| Placebo | 1.0 | 10.3 | 12.1 | 13.1 | 13.6 | 14.6 | 17.9 | 15.9 | 18.1 | 15.5 | 18.8 | 16.0 | 16.0 | 19.1 | 19.8 | 16.1 | 18.8 | 19.5 | 19.2 | 16.3 | 18.8 | 18.4 | 18.3 | 15.7 |
| Varenicline 1.0 mg BID | 1.3 | 18.8 | 26.3 | 30.4 | 33.4 | 35.8 | 39.5 | 37.4 | 41.6 | 38.7 | 42.5 | 39.6 | 36.8 | 39.5 | 38.5 | 33.1 | 36.4 | 36.2 | 35.7 | 30.8 | 33.9 | 33.8 | 33.0 | 29.8 |
"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | |
| Bupropion 150 mg BID | 1.0 | 21.3 | 26.6 | 27.7 | 29.8 | 31.4 | 35.2 | 31.0 | 34.9 | 31.0 | 34.1 | 30.5 | 30.7 | 33.5 | 33.2 | 28.5 | 31.9 | 31.3 | 31.2 | 27.5 | 30.3 | 29.9 | 30.6 | 26.0 |
| NRT Patch | 1.2 | 15.5 | 22.1 | 25.9 | 27.8 | 30.4 | 35.1 | 31.4 | 34.8 | 31.1 | 34.9 | 30.4 | 29.9 | 32.0 | 32.4 | 28.1 | 31.4 | 31.7 | 31.2 | 26.3 | 29.3 | 29.0 | 28.3 | 27.0 |
| Placebo | 1.5 | 11.4 | 13.6 | 14.5 | 14.9 | 15.9 | 19.2 | 16.7 | 19.0 | 16.9 | 20.8 | 17.8 | 17.2 | 20.4 | 21.3 | 18.2 | 20.1 | 20.8 | 20.8 | 18.2 | 20.1 | 20.3 | 20.3 | 17.4 |
| Varenicline 1.0 mg BID | 1.7 | 20.9 | 30.0 | 34.3 | 38.4 | 41.0 | 44.4 | 42.3 | 47.1 | 42.4 | 46.6 | 44.4 | 41.1 | 44.5 | 43.8 | 37.2 | 40.7 | 40.9 | 39.9 | 35.1 | 38.1 | 38.7 | 37.6 | 33.6 |
"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | |
| Bupropion 150 mg BID | 1.2 | 14.6 | 18.1 | 21.3 | 21.8 | 22.7 | 25.4 | 22.1 | 26.0 | 24.3 | 27.4 | 23.9 | 22.6 | 25.0 | 25.3 | 21.9 | 24.0 | 24.5 | 24.7 | 20.4 | 23.2 | 22.9 | 23.5 | 20.4 |
| NRT Patch | 0.7 | 13.0 | 17.9 | 21.1 | 22.4 | 23.3 | 27.5 | 24.6 | 29.4 | 25.0 | 29.4 | 24.9 | 24.0 | 26.8 | 26.0 | 21.8 | 24.8 | 24.7 | 25.1 | 25.1 | 23.7 | 23.6 | 22.2 | 20.1 |
| Placebo | 0.5 | 9.2 | 10.7 | 11.8 | 12.4 | 13.4 | 16.6 | 15.0 | 17.2 | 14.0 | 17.2 | 14.2 | 14.8 | 17.8 | 18.3 | 13.9 | 17.4 | 18.2 | 17.6 | 17.6 | 17.5 | 16.5 | 16.4 | 14.0 |
| Varenicline 1.0 mg BID | 1.0 | 16.8 | 22.7 | 26.6 | 28.5 | 30.8 | 34.8 | 32.7 | 36.2 | 35.1 | 38.6 | 35.0 | 32.7 | 34.7 | 33.4 | 29.1 | 32.3 | 31.7 | 31.6 | 26.6 | 29.7 | 29.1 | 28.5 | 26.1 |
"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | percentage of participants (Least Squares Mean) | |
|---|---|---|
| Non-psychiatric cohort (N=3984) | Psychiatric cohort (N= 4074) | |
| Bupropion 150 mg BID | 2.44 | 6.62 |
| NRT Patch | 2.31 | 5.20 |
| Placebo | 2.52 | 4.83 |
| Varenicline 1.0 mg BID | 1.25 | 6.42 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | Units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 1989, 1976, 1985, 1987) | Week 2 (N= 1938, 1937, 1931, 1929) | Week 3 (N= 1882, 1891, 1881, 1867) | Week 4 (N= 1858, 1854, 1863, 1831) | Week 5 (N= 1829, 1815, 1820, 1797) | Week 6 (N= 1816, 1807, 1821, 1771) | Week 8 (N= 1755, 1754, 1755, 1736) | Week 10 (N= 1717, 1709, 1716, 1669) | Week 12 (N= 1562, 1571, 1548, 1491) | Week 13 (N= 1610, 1608, 1603, 1570) | Week 16 (N= 1579, 1602, 1566, 1537) | Week 20 (N= 1555, 1569, 1525, 1509) | Week 24 (N= 1528, 1512, 1495, 1487) | |
| Bupropion 150 mg BID | 5.61 | 5.06 | 4.60 | 4.39 | 4.16 | 4.05 | 4.10 | 3.86 | 3.79 | 3.66 | 3.77 | 3.73 | 3.80 |
| NRT Patch | 4.95 | 4.74 | 4.48 | 4.31 | 4.08 | 4.01 | 3.96 | 4.00 | 3.78 | 3.71 | 3.78 | 3.72 | 3.82 |
| Placebo | 5.05 | 4.80 | 4.38 | 4.39 | 4.14 | 4.09 | 4.12 | 4.04 | 3.95 | 3.70 | 3.82 | 3.75 | 3.62 |
| Varenicline 1.0 mg BID | 5.03 | 4.68 | 4.31 | 4.15 | 3.94 | 3.82 | 3.82 | 3.85 | 3.64 | 3.60 | 3.67 | 3.65 | 3.62 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | Units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 1026, 1017, 1015, 1015) | Week 2 (N= 1005, 1004, 996, 995) | Week 3 (N= 947, 961, 945, 926) | Week 4 (N= 935, 938, 929, 908) | Week 5 (N= 918, 918, 914, 895) | Week 6 (N= 917, 914, 912, 874) | Week 8 (N= 887, 893, 878, 859) | Week 10 (N= 864, 865, 864, 823) | Week 12 (N= 790, 803, 798, 749) | Week 13 (N= 813, 812, 814, 763) | Week 16 (N= 795, 805, 791, 748) | Week 20 (N= 784, 784, 763, 737) | Week 24 (N= 770, 764, 758, 729) | |
| Bupropion 150 mg BID | 7.58 | 6.99 | 6.51 | 6.36 | 6.03 | 5.87 | 5.96 | 5.72 | 5.66 | 5.44 | 5.62 | 5.54 | 5.69 |
| NRT Patch | 6.82 | 6.64 | 6.30 | 6.16 | 5.82 | 5.62 | 5.63 | 5.64 | 5.44 | 5.36 | 5.44 | 5.46 | 5.57 |
| Placebo | 6.70 | 6.42 | 6.02 | 6.04 | 5.80 | 5.75 | 5.63 | 5.55 | 5.42 | 5.09 | 5.37 | 5.26 | 5.04 |
| Varenicline 1.0 mg BID | 6.76 | 6.42 | 5.99 | 5.87 | 5.58 | 5.39 | 5.43 | 5.38 | 5.17 | 5.06 | 5.26 | 5.17 | 5.21 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24
| Intervention | Units on a scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (N= 984, 972, 989, 992) | Week 2 (N= 961, 954, 963, 970) | Week 3 (N= 935, 930, 936, 941) | Week 4 (N= 923, 916, 934, 923) | Week 5 (N= 911, 897, 906, 902) | Week 6 (N= 899, 893, 909, 897) | Week 8 (N= 868, 861, 877, 877) | Week 10 (N= 853, 844, 852, 846) | Week 12 (N= 772, 768, 750, 742) | Week 13 (N= 797, 796, 789, 807) | Week 16 (N= 784, 797, 775, 789) | Week 20 (N= 771, 785, 762, 772) | Week 24 (N= 758, 748, 737, 758) | |
| Bupropion 150 mg BID | 3.58 | 3.07 | 2.64 | 2.36 | 2.24 | 2.18 | 2.16 | 1.96 | 1.83 | 1.85 | 1.90 | 1.93 | 1.87 |
| NRT Patch | 3.06 | 2.84 | 2.63 | 2.46 | 2.32 | 2.40 | 2.28 | 2.33 | 2.01 | 2.01 | 2.09 | 1.97 | 2.01 |
| Placebo | 3.38 | 3.20 | 2.77 | 2.77 | 2.48 | 2.48 | 2.64 | 2.57 | 2.46 | 2.38 | 2.34 | 2.31 | 2.25 |
| Varenicline 1.0 mg BID | 3.26 | 2.91 | 2.61 | 2.40 | 2.29 | 2.23 | 2.17 | 2.29 | 2.07 | 2.11 | 2.05 | 2.10 | 2.01 |
"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Non-psychiatric cohort (N= 990, 989, 1006, 999) | Psychiatric cohort (N= 1026, 1017, 1016, 1015) | Overall (N= 2016, 2006, 2022, 2014) | |
| Bupropion 150 mg BID | 2.2 | 6.7 | 4.5 |
| NRT Patch | 2.5 | 5.2 | 3.9 |
| Placebo | 2.4 | 4.9 | 3.7 |
| Varenicline 1.0 mg BID | 1.3 | 6.5 | 4.0 |
"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Non-psychiatric cohort (N= 990, 989, 1006, 999) | Psychiatric cohort (N= 1026, 1017, 1016, 1015) | Overall (N= 2016, 2006, 2022, 2014) | |
| Bupropion 150 mg BID | 0.4 | 1.4 | 0.9 |
| NRT Patch | 0.3 | 1.4 | 0.8 |
| Placebo | 0.5 | 1.3 | 0.9 |
| Varenicline 1.0 mg BID | 0.1 | 1.4 | 0.7 |
The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below. (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling Abnormal | Hostility | Agitation | Aggression | Delusions | Hallucination | Mania | Panic Disorder | Paranoia | Psychosis | Homicidal Ideation | Suicidal Behavior | Suicidal Ideation | Suicide | |
| Bupropion 150 mg BID | 5 | 4 | 1 | 1 | 40 | 12 | 1 | 4 | 10 | 20 | 1 | 2 | 0 | 2 | 3 | 0 |
| NRT Patch | 6 | 7 | 0 | 1 | 40 | 9 | 2 | 2 | 5 | 14 | 0 | 4 | 1 | 1 | 5 | 0 |
| Placebo | 5 | 6 | 0 | 0 | 33 | 11 | 0 | 2 | 8 | 10 | 2 | 1 | 0 | 1 | 5 | 1 |
| Varenicline 1.0 mg BID | 5 | 7 | 0 | 0 | 35 | 17 | 1 | 6 | 7 | 7 | 1 | 4 | 0 | 1 | 5 | 0 |
"The NPS AE endpoint was the occurrence of at least 1 treatment-emergent severe AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent severe AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling Abnormal | Hostility | Agitation | Aggression | Delusions | Hallucination | Mania | Panic Disorder | Paranoia | Psychosis | Suicidal Behavior | Suicidal Ideation | Suicide | Homicidal Ideation | |
| Bupropion 150 mg BID | 5 | 4 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 0 | 0 | 0 |
| NRT Patch | 6 | 7 | 0 | 1 | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 1 | 0 | 1 |
| Placebo | 5 | 6 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 0 | 1 | 0 |
| Varenicline 1.0 mg BID | 5 | 7 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 1 | 4 | 1 | 1 | 0 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety (severe) | Depression (severe) | Feeling abnormal (severe only) | Hostility (severe) | Agitation (moderate and severe) | Aggression (moderate and severe) | Delusions (moderate and severe) | Hallucinations (moderate and severe) | Mania (moderate and severe) | Panic (moderate and severe) | Paranoia (moderate and severe) | Psychosis (moderate and severe) | Homicidal ideation (moderate and severe) | Suicidal behavior (moderate and severe) | Suicidal ideation (moderate and severe) | Suicide (moderate and severe) | |
| Bupropion 150 mg BID | 1 | 0 | 0 | 1 | 11 | 3 | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 1 | 1 | 0 |
| NRT Patch | 0 | 0 | 0 | 1 | 19 | 2 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| Placebo | 3 | 0 | 0 | 0 | 11 | 3 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 3 | 1 |
| Varenicline 1.0 mg BID | 0 | 1 | 0 | 0 | 10 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety (severe) | Depression (severe) | Feeling abnormal (severe only) | Hostility (severe) | Agitation (moderate and severe) | Aggression (moderate and severe) | Delusions (moderate and severe) | Hallucinations (moderate and severe) | Mania (moderate and severe) | Panic (moderate and severe) | Paranoia (moderate and severe) | Psychosis (moderate and severe) | Homicidal ideation (moderate and severe) | Suicidal behavior (moderate and severe) | Suicidal ideation (moderate and severe) | Suicide (moderate and severe) | |
| Bupropion 150 mg BID | 4 | 4 | 1 | 0 | 29 | 9 | 1 | 4 | 9 | 16 | 0 | 2 | 0 | 1 | 2 | 0 |
| NRT Patch | 6 | 7 | 0 | 0 | 21 | 7 | 1 | 2 | 3 | 13 | 0 | 3 | 0 | 0 | 3 | 0 |
| Placebo | 2 | 6 | 0 | 0 | 22 | 8 | 0 | 2 | 6 | 7 | 2 | 1 | 0 | 1 | 2 | 0 |
| Varenicline 1.0 mg BID | 5 | 6 | 0 | 0 | 25 | 14 | 1 | 5 | 7 | 7 | 1 | 4 | 0 | 1 | 5 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling abnormal | Hostility | Agitation | Aggression | Delusions | Hallucinations | Mania | Panic | Paranoia | Psychosis | Homicidal ideation | Suicidal behavior | Suicidal ideation | Suicide | |
| Bupropion 150 mg BID | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| NRT Patch | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Varenicline 1.0 mg BID | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | Depression | Feeling abnormal | Hostility | Agitation | Aggression | Delusions | Hallucinations | Mania | Panic | Paranoia | Psychosis | Homicidal ideation | Suicidal behavior | Suicidal ideation | Suicide | |
| Bupropion 150 mg BID | 4 | 4 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| NRT Patch | 6 | 7 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Placebo | 2 | 6 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Varenicline 1.0 mg BID | 5 | 6 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants with positive responses (Number) | |||||
|---|---|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | Suicidal Ideation (Screening lifetime) | Suicidal Behavior (Baseline) | Suicidal Ideation (Baseline) | Suicidal Behavior (treatment emergent 12 weeks) | Suicidal Ideation (treatment emergent 12 weeks) | |
| Bupropion 150 mg BID | 9 | 43 | 0 | 1 | 0 | 4 |
| NRT Patch | 7 | 50 | 0 | 0 | 1 | 3 |
| Placebo | 6 | 49 | 0 | 1 | 1 | 6 |
| Varenicline 1.0 mg BID | 6 | 48 | 0 | 0 | 0 | 7 |
"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants with positive responses (Number) | |||||
|---|---|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | Suicidal Ideation (Screening lifetime) | Suicidal Behavior (Baseline) | Suicidal Ideation (Baseline) | Suicidal Behavior (treatment emergent 12 weeks) | Suicidal Ideation (treatment emergent 12 weeks) | |
| Bupropion 150 mg BID | 152 | 400 | 0 | 6 | 1 | 19 |
| NRT Patch | 118 | 383 | 0 | 2 | 1 | 23 |
| Placebo | 129 | 398 | 1 | 4 | 3 | 31 |
| Varenicline 1.0 mg BID | 143 | 386 | 0 | 6 | 0 | 34 |
"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
| Intervention | participants with positive responses (Number) | |||||
|---|---|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | Suicidal Ideation (Screening lifetime) | Suicidal Behavior (Baseline) | Suicidal Ideation (Baseline) | Suicidal Behavior (treatment emergent 12 weeks) | Suicidal Ideation (treatment emergent 12 weeks) | |
| Bupropion 150 mg BID | 143 | 357 | 0 | 5 | 1 | 15 |
| NRT Patch | 111 | 333 | 0 | 2 | 0 | 20 |
| Placebo | 123 | 349 | 1 | 3 | 2 | 25 |
| Varenicline 1.0 mg BID | 137 | 338 | 0 | 6 | 0 | 27 |
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
Relapse in symptoms of major depression defined as a QIDS-C16 => 11 among those achieving remission in the acute phase. (NCT01421342)
Timeframe: Within 36 weeks after randomization (initiation of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 26 |
| Augmenting: Antidepressant + Bupropion-SR | 35 |
| Augmenting: Antidepressant + Aripiprazole | 37 |
Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of <= 5 for two consecutive visits. (NCT01421342)
Timeframe: During acute phase (12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 114 |
| Augmenting: Antidepressant + Bupropion-SR | 136 |
| Augmenting: Antidepressant + Aripiprazole | 146 |
Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 319 |
| Augmenting: Antidepressant + Bupropion-SR | 332 |
| Augmenting: Antidepressant + Aripiprazole | 375 |
Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved). (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 356 |
| Augmenting: Antidepressant + Bupropion-SR | 376 |
| Augmenting: Antidepressant + Aripiprazole | 400 |
Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Varenicline w/o DRD2 A1 Allele | 8.084 |
| Varenicline With DRD2 A1 Allele | 6.847 |
| Bupropion w/o DRD2 A1 Allele | 7.588 |
| Bupropion With DRD2 A1 Allele | 8.362 |
| Placebo w/o DRD2 A1 Allele | 8.65 |
| Placebo With DRD2 A1 Allele | 10.799 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 0.001 | 0.001 | 0 | 0.001 |
| Bupropion With DRD2 A1 Allele | -0.001 | -0.002 | -0.001 | -0.001 |
| Placebo w/o DRD2 A1 Allele | 0 | 0 | 0 | 0 |
| Placebo With DRD2 A1 Allele | -0.005 | -0.004 | -0.004 | -0.004 |
| Varenicline w/o DRD2 A1 Allele | 0.003 | 0.003 | 0.003 | 0.003 |
| Varenicline With DRD2 A1 Allele | -0.001 | -0.001 | 0 | -0.001 |
Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | microvolts (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion | 64.7 | 73.1 | 65.4 | 64.9 |
| Placebo | 65.6 | 65.6 | 64.7 | 72.5 |
| Varenicline | 66.6 | 70.9 | 66.7 | 59.6 |
The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | microvolts (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 66.2 | 78.6 | 71.3 | 73.9 |
| Bupropion With DRD2 A1 Allele | 66 | 71.3 | 63.3 | 61.2 |
| Placebo w/o DRD2 A1 Allele | 67.3 | 74 | 68.5 | 79.7 |
| Placebo With DRD2 A1 Allele | 68.1 | 68.1 | 63.8 | 67.8 |
| Varenicline w/o DRD2 A1 Allele | 66.5 | 70.5 | 65.5 | 55.3 |
| Varenicline With DRD2 A1 Allele | 69.9 | 75.1 | 72 | 67.2 |
Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | beats per minute (Least Squares Mean) | |||
|---|---|---|---|---|
| Heart Rate response to Cigarette Stimuli | Heart Rate response to Negative Stimuli | Heart Rate response to Positive Stimuli | Heart Rate response to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 71.427 | 71.077 | 71.518 | 71.706 |
| Bupropion With DRD2 A1 Allele | 69.836 | 69.595 | 70.404 | 70.234 |
| Placebo w/o DRD2 A1 Allele | 65.966 | 65.768 | 65.787 | 65.237 |
| Placebo With DRD2 A1 Allele | 65.276 | 65.569 | 65.927 | 66.04 |
| Varenicline w/o DRD2 A1 Allele | 69.731 | 69.562 | 69.151 | 69.621 |
| Varenicline With DRD2 A1 Allele | 68.652 | 68.078 | 68.711 | 68.969 |
Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items. (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Smoking Satisfaction | Psychological Reward | Aversion | Enjoyment of Respiratory Tract Sensation | Craving Reduction | |
| Bupropion w/o DRD2 A1 Allele | 4.064 | 2.519 | 1.988 | 4.096 | 4.564 |
| Bupropion With DRD2 A1 Allele | 3.369 | 2.723 | 1.79 | 1.955 | 6.628 |
| Placebo w/o DRD2 A1 Allele | 3.025 | 3.575 | 1.808 | 3.711 | 4.486 |
| Placebo With DRD2 A1 Allele | 3.515 | 3.246 | 1.69 | 2.783 | 4.673 |
| Varenicline w/o DRD2 A1 Allele | 2.895 | 2.819 | 1.612 | 1.912 | 4.531 |
| Varenicline With DRD2 A1 Allele | 2.591 | 2.155 | 1.694 | 1.703 | 3.952 |
Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | Microsiemens (Least Squares Mean) | |||
|---|---|---|---|---|
| Skin conductance to Cigarette Stimuli | Skin conductance to Negative Stimuli | Skin conductance to Positive Stimuli | Skin conductance to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 2.275 | 2.31 | 2.299 | 2.369 |
| Bupropion With DRD2 A1 Allele | 1.797 | 1.695 | 1.7 | 1.699 |
| Placebo w/o DRD2 A1 Allele | 2.272 | 2.355 | 2.296 | 2.362 |
| Placebo With DRD2 A1 Allele | 2.443 | 2.485 | 2.565 | 2.559 |
| Varenicline w/o DRD2 A1 Allele | 2.301 | 2.295 | 2.256 | 2.261 |
| Varenicline With DRD2 A1 Allele | 2.016 | 1.969 | 1.984 | 2.017 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 months
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion | -0.01 | -0.009 | -0.01 | -0.008 |
| Placebo | -0.008 | -0.007 | -0.007 | -0.007 |
| Varenicline | -0.003 | -0.004 | -0.003 | -0.004 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 Month
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 0 | 0 | 0 | 0.001 |
| Bupropion With DRD2 A1 Allele | -0.003 | -0.004 | -0.003 | -0.002 |
| Placebo w/o DRD2 A1 Allele | -0.001 | -0.001 | -0.001 | -0.001 |
| Placebo With DRD2 A1 Allele | -0.004 | -0.004 | -0.004 | -0.003 |
| Varenicline w/o DRD2 A1 Allele | 0.001 | 0.002 | 0.001 | 0.001 |
| Varenicline With DRD2 A1 Allele | -0.004 | -0.005 | -0.005 | -0.005 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigaretee Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion | -0.002 | -0.003 | -0.003 | -0.001 |
| Placebo | -0.006 | -0.005 | -0.005 | -0.005 |
| Varenicline | 0.007 | 0.008 | 0.01 | 0.008 |
Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) | |
|---|---|---|
| Positive Affect | Negative Affect | |
| Bupropion w/o DRD2 A1 Allele | 36.429 | 15.782 |
| Bupropion With DRD2 A1 Allele | 35.281 | 16.385 |
| Placebo w/o DRD2 A1 Allele | 33.672 | 18.017 |
| Placebo With DRD2 A1 Allele | 33.984 | 18.902 |
| Varenicline w/o DRD2 A1 Allele | 35.507 | 15.93 |
| Varenicline With DRD2 A1 Allele | 37.315 | 14.98 |
Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Anger | Anxiety | Concentration | Craving | Hunger | Sadness | Sleep | |
| Bupropion w/o DRD2 A1 Allele | 4.28 | 6.587 | 4.238 | 6.814 | 9.79 | 4.005 | 9.672 |
| Bupropion With DRD2 A1 Allele | 4.41 | 6.587 | 3.935 | 6.78 | 11.082 | 4.338 | 9.528 |
| Placebo w/o DRD2 A1 Allele | 5.584 | 7.785 | 4.764 | 9.024 | 11.207 | 5.293 | 9.078 |
| Placebo With DRD2 A1 Allele | 5.752 | 7.915 | 4.951 | 8.696 | 11.044 | 5.865 | 8.629 |
| Varenicline w/o DRD2 A1 Allele | 4.394 | 6.218 | 3.743 | 6.646 | 11.016 | 4.246 | 7.721 |
| Varenicline With DRD2 A1 Allele | 4.222 | 5.873 | 3.407 | 6.252 | 10.707 | 3.738 | 8.153 |
Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning (NCT00519428)
Timeframe: 12 weeks
| Intervention | units on the SAS scale (Mean) |
|---|---|
| Escitalopram + Bupropion | 2.65 |
| Escitalopram | 2.63 |
| Bupropion | 2.74 |
"The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).~The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction." (NCT00519428)
Timeframe: 12 weeks
| Intervention | units on the Q-LES-Q scale (Mean) |
|---|---|
| Escitalopram + Bupropion | 3.0 |
| Escitalopram | 3.0 |
| Bupropion | 3.1 |
Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] > 7 once HAMD-D 17 <= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate. (NCT00519428)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion | 52 |
| Escitalopram | 46 |
| Bupropion | 34 |
"Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.~0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression~≥ 23 = Very Severe Depression" (NCT00519428)
Timeframe: 12 weeks
| Intervention | units on Hamilton Rating Scale for Depre (Mean) |
|---|---|
| Escitalopram + Bupropion | 10 |
| Escitalopram | 9 |
| Bupropion | 12 |
Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05. (NCT00519428)
Timeframe: 12 weeks
| Intervention | weeks (Mean) |
|---|---|
| Escitalopram + Bupropion | 8 |
| Escitalopram | 9 |
| Bupropion | 10 |
"Number of participants who report Not Smoking (not even a puff) in past 7 days when asked at week 8" (NCT01015170)
Timeframe: End of Treatment (8 weeks after Zyban start date)
| Intervention | participants (Number) | |
|---|---|---|
| Still smoking | Quit smoking | |
| Nicotine Replacement & Behavioural Support | 109 | 106 |
26 reviews available for bupropion and Depression
| Article | Year |
|---|---|
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
Topics: Alkaloids; Antidepressive Agents; Azetidines; Azocines; Depression; Humans; Ligands; Molecular Targe | 2014 |
Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis.
Topics: Adult; Antidepressive Agents; Autoreceptors; Bupropion; Depression; Drug Therapy, Combination; Human | 2022 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult.
Topics: Aged; Bupropion; Cognitive Dysfunction; Depression; Humans | 2023 |
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.
Topics: Adult; Antidepressive Agents; Bupropion; Depression; Depressive Disorder, Major; Dextromethorphan; H | 2023 |
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Attention Deficit Disorder with Hyperactiv | 2021 |
Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.
Topics: Bupropion; Cost-Benefit Analysis; Depression; Drug Costs; Electronic Nicotine Delivery Systems; Huma | 2021 |
Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: A systematic review and meta-analysis.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Male; Smoking; Smok | 2017 |
Pharmacotherapy for Perinatal Depression.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antidepressive Agents, Tricyclic; Autism Spectru | 2018 |
Meta-analysis: Second generation antidepressants and headache.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Depression; Double- | 2018 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disor | 2019 |
[Antidepressants in epilepsy].
Topics: Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Clinical Trials | 2013 |
Bupropion in the depression-related sexual dysfunction: a systematic review.
Topics: Bupropion; Databases, Bibliographic; Depression; Female; Humans; Male; Selective Serotonin Reuptake | 2014 |
Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
Topics: Adolescent; Adult; Affect; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Bupropion | 2016 |
Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepres | 2017 |
Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?
Topics: Animals; Binding Sites; Bupropion; Catecholamine Plasma Membrane Transport Proteins; Depression; Hum | 2009 |
Use of sustained-release bupropion in specific patient populations for smoking cessation.
Topics: Alcoholism; Body Weight; Bupropion; Delayed-Action Preparations; Depression; Dopamine Uptake Inhibit | 2002 |
Review of bupropion for smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Delayed-Action Prepara | 2003 |
[Treatment of tobacco dependence: brief and intensive clinical intervention].
Topics: Anxiety; Bupropion; Cognitive Behavioral Therapy; Depression; Dopamine Uptake Inhibitors; Ganglionic | 2004 |
Psychiatric morbidity in psoriasis: a review.
Topics: Adaptation, Psychological; Adrenal Cortex Hormones; Antidepressive Agents; Bupropion; Depression; Hu | 2004 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Review: Bupropion and SSRI-induced side effects.
Topics: Affective Symptoms; Bupropion; Depression; Dopamine Uptake Inhibitors; Drug Interactions; Drug Thera | 2008 |
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Bu | 1997 |
Nicotine dependence: the role for antidepressants and anxiolytics.
Topics: Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorde | 2002 |
Major depression: its recognition and treatment. Part 2. Second-generation and newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Clomipramine; Depression; Female; Fluoxetine; Humans; Male; Maprot | 1992 |
Bupropion: new therapy for depression.
Topics: Antidepressive Agents; Bupropion; Depression; Humans; Propiophenones | 1990 |
43 trials available for bupropion and Depression
| Article | Year |
|---|---|
Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression.
Topics: Aging; Antidepressive Agents; Brain; Bupropion; Depression; Humans; Magnetic Resonance Imaging | 2022 |
The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial.
Topics: Bupropion; Depression; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Polyesters; Sm | 2022 |
Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Humans; | 2022 |
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major | 2023 |
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major | 2023 |
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major | 2023 |
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major | 2023 |
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline | 2023 |
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline | 2023 |
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline | 2023 |
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline | 2023 |
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
Topics: Aged; Antidepressive Agents; Aripiprazole; Bupropion; Depression; Drug Therapy, Combination; Humans; | 2023 |
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Bupropion; Canada; Depression; Double-Blind Method; Escital | 2023 |
A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Breast Neoplasms; Bupropion; Cancer Survivors | 2020 |
Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.
Topics: Adult; Antidepressive Agents; Biomarkers; Bupropion; Depression; Drug Therapy, Combination; Female; | 2017 |
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body | 2018 |
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio | 2019 |
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Aripiprazole; Bupropion; Cost-Benefit Analysi | 2018 |
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Del | 2013 |
Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Cyclohexan | 2013 |
Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies.
Topics: Adult; Alpha Rhythm; Antidepressive Agents, Second-Generation; Brain Mapping; Bupropion; Citalopram; | 2014 |
Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Depression; Double-Blind Method; Drug The | 2014 |
A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms?
Topics: Adolescent; Adult; Aged; Bupropion; Chronic Disease; Cognitive Behavioral Therapy; Counseling; Depre | 2015 |
Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation.
Topics: Adult; Bupropion; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; | 2015 |
Treatment of maternal depression in a medication clinical trial and its effect on children.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Child; Child of Impaired Parents; Citalo | 2015 |
Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; De | 2009 |
Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures.
Topics: Administration, Oral; Adult; Bupropion; Chewing Gum; Combined Modality Therapy; Counseling; Depressi | 2009 |
A bupropion smoking cessation clinical trial for cancer patients.
Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Depression; Depressi | 2010 |
The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments.
Topics: Adult; Antidepressive Agents; Bupropion; Depression; Female; Humans; Male; Middle Aged; Predictive V | 2010 |
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; | 2011 |
Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
Topics: Adult; Aged; Biomarkers; Black or African American; Bupropion; Cotinine; Depression; Dopamine Uptake | 2012 |
Bupropion pre-treatment of endotoxin-induced depressive symptoms.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Bupropion; Chemokines; Cross-Over S | 2013 |
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Bupropion; Cholesterol; Delayed-Action Prepa | 2002 |
Targeting smokers at increased risk for relapse: treating women and those with a history of depression.
Topics: Administration, Cutaneous; Bupropion; Depression; Dopamine Uptake Inhibitors; Female; Humans; Male; | 2003 |
Assessing the effects of bupropion SR on mood dimensions of depression.
Topics: Administration, Oral; Adult; Affect; Antidepressive Agents, Second-Generation; Bupropion; Depression | 2004 |
Depressed smokers and stage of change: implications for treatment interventions.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Depression; Female; Humans; | 2004 |
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 2005 |
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Delayed-Action Preparati | 2006 |
Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Depression; D | 2005 |
The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion.
Topics: Adult; Attitude to Health; Black or African American; Bupropion; Comorbidity; Depression; Dopamine U | 2005 |
Bupropion improves sexual functioning in depressed minority women: an open-label switch study.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; | 2006 |
Bupropion and cognitive-behavioral treatment for depression in smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Combined M | 2007 |
Comparative efficacy and safety of bupropion and placebo in the treatment of depression.
Topics: Adult; Bupropion; Clinical Trials as Topic; Depression; Double-Blind Method; Female; Humans; Male; M | 1983 |
Bupropion: study of treatment in depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depression; Fem | 1983 |
Determination of plasma bupropion and its relationship to therapeutic effect.
Topics: Amitriptyline; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depression; Double-Blind | 1984 |
Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamin | 1995 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
Safety profile of sustained-release bupropion in depression: results of three clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Del | 1999 |
Efficacy of sustained-release bupropion in neuropathic pain: an open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action | 2000 |
83 other studies available for bupropion and Depression
| Article | Year |
|---|---|
Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?
Topics: Bupropion; Depression; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; | 2022 |
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methy | 2022 |
Dextromethorphan/bupropion (Auvelity) for depression.
Topics: Bupropion; Depression; Dextromethorphan; Humans; Selective Serotonin Reuptake Inhibitors; Smoking Ce | 2022 |
Augmentation With Aripiprazole or Bupropion, or a Switch to Nortriptyline, Effective for Treatment-Resistant Depression in Older Adults.
Topics: Aged; Aripiprazole; Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Humans; Nortrip | 2023 |
Increased depression-like behaviors with altered brain dopamine metabolisms in male mice housed in large cages are alleviated by bupropion.
Topics: Anhedonia; Animals; Brain; Bupropion; Depression; Dopamine; Female; Housing; Male; Mice; Norepinephr | 2023 |
Using prefrontal and midline right frontal EEG-derived theta cordance and depressive symptoms to predict the differential response or remission to antidepressant treatment in major depressive disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Electro | 2020 |
Delayed Onset of Bupropion-Induced Urticaria.
Topics: Adolescent; Bupropion; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Humans; Male; Urticaria | 2020 |
Formulation, Characterization and Comparative Pharmacokinetic Study of Bupropion Floating Raft System as a Promising Approach for Treating Depression.
Topics: Bupropion; Delayed-Action Preparations; Depression; Drug Delivery Systems; Humans; Solubility; Table | 2020 |
Methylglyoxal-Mediated Dopamine Depletion, Working Memory Deficit, and Depression-Like Behavior Are Prevented by a Dopamine/Noradrenaline Reuptake Inhibitor.
Topics: Animals; Bupropion; Depression; Dopamine; Dopamine Uptake Inhibitors; Female; Glutathione; Immobiliz | 2021 |
Evidence of hypoglycemic anhedonia and modulation by bupropion in rats.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Appetitive Behavior; Bupropion; Deoxyg | 2021 |
A 19-Year-Old Woman with a History of Depression and Fatal Cardiorespiratory Failure Following an Overdose of Prescribed Bupropion.
Topics: Adolescent; Adult; Bupropion; Depression; Drug Overdose; Female; Humans; Seizures; Shock, Cardiogeni | 2021 |
Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Emotions; Female; Humans; Ma | 2018 |
Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Fluoxetine; Ganglia, Spinal; Humans | 2018 |
Homicidal Ideation and Individuals on the Autism Spectrum.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder; Bup | 2019 |
Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Circadian Rhythm; Depression; Dopamine; | 2019 |
The effect of bupropion augmentation of minocycline in the treatment of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Bupropion; Depression; Depressive Disorder; | 2019 |
Varenicline may reduce negative effect while aiding smoking cessation.
Topics: Benzazepines; Bupropion; Counseling; Depression; Female; Humans; Male; Nicotinic Agonists; Quinoxali | 2014 |
Varenicline, smoking cessation, and neuropsychiatric adverse events.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Mal | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study.
Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Cohort Studies; Depression; England; Female; Human | 2013 |
Still not clear that smoking cessation drugs do not cause psychiatric symptoms.
Topics: Benzazepines; Bupropion; Depression; Female; Humans; Male; Quinoxalines; Self-Injurious Behavior; Sm | 2013 |
Authors' reply to Davies.
Topics: Benzazepines; Bupropion; Depression; Female; Humans; Male; Quinoxalines; Self-Injurious Behavior; Sm | 2013 |
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Sec | 2013 |
Effects of bupropion and pramipexole on cell proliferation in the hippocampus of adrenocorticotropic hormone-treated rats.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Benzothiazoles; Bupropion; Cell Prolife | 2014 |
Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion.
Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depression; Drug Therapy, Combination; Female | 2014 |
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
Topics: Animals; Antidepressive Agents; Benzazepines; Benzophenones; Bupropion; Cannabinoid Receptor Antagon | 2014 |
Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington's Disease with Dopaminergic Dysfunction.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Dopamine Uptake Inhibitors; | 2012 |
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice.
Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; I | 2014 |
Effect of Treating Mothers' Depression on Children's Well-Being.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Child of Impaired Parents; Citalopram; Depressi | 2015 |
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.
Topics: Adult; Bupropion; Cardiovascular Diseases; Depression; Dopamine Uptake Inhibitors; Female; Humans; M | 2015 |
Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Drug Synergism; Drug Therap | 2015 |
Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats.
Topics: Analgesics; Analgesics, Opioid; Animals; Bupropion; Depression; Disease Models, Animal; Dose-Respons | 2016 |
Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid.
Topics: Adult; Amniotic Fluid; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Feta | 2016 |
Do COPD treatment guidelines correctly address the treatment of smoking?
Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Practice Guidelines as Topic; Pulmonary Disease, | 2016 |
Wellbutrin versus generic bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; Dopami | 2008 |
Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents, Second-Generatio | 2008 |
Severe constipation associated with extended-release bupropion therapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cathartics; Constipation; Delayed-Action | 2008 |
Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion.
Topics: Animals; Bupropion; Depression; Dose-Response Relationship, Drug; Drug Administration Routes; Gene E | 2008 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
Struck from behind: maintaining quality of life with chronic low back pain.
Topics: Accidents, Traffic; Activities of Daily Living; Adult; Analgesics, Opioid; Bupropion; Depression; Do | 2009 |
Bupropion for depression in schizophrenia: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Humans; Male; Schizophrenia | 2010 |
Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant?
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Co | 2010 |
Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats.
Topics: Animals; Bupropion; Chromatography, High Pressure Liquid; Cosyntropin; Depression; Dopamine; Dopamin | 2010 |
Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; | 2010 |
Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; Humans; | 2010 |
Regulatory role of the dopamine and norepinephrine transporters in pentylenetetrazol-kindled mice: association with effect of antidepressants.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Bupropion; | 2011 |
Suicidal behavior and depression in smoking cessation treatments.
Topics: Adult; Benzazepines; Bupropion; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic A | 2011 |
Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cardiotoxins; Citalopram; Delayed-Action | 2012 |
Reward responsiveness and fatigue in multiple sclerosis.
Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso | 2013 |
[Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy].
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depression; F | 2002 |
Smoking and depression.
Topics: Bupropion; Depression; Genetic Predisposition to Disease; Humans; Smoking; Tobacco Use Disorder; Uni | 2002 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, An | 2003 |
Bupropion should be included in article on antidepressants.
Topics: Antidepressive Agents; Bupropion; Depression; Humans; Selective Serotonin Reuptake Inhibitors | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test.
Topics: Animals; Benzazepines; Bupropion; Depression; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose | 2004 |
Acceptance of nicotine dependence treatment among currently depressed smokers.
Topics: Adult; Behavior Therapy; Bupropion; Community Mental Health Centers; Counseling; Depression; Dopamin | 2005 |
Bupropion-induced subacute cutaneous lupus erythematosus.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Immunosuppre | 2005 |
Assessment and management of women's sexual dysfunctions: problematic desire and arousal.
Topics: Adult; Androgens; Bupropion; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopa | 2005 |
Psychopharmacology of smoking cessation in patients with mental illness.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Arousal; Bupropion; Citalopram; Depression; Depre | 2006 |
Editorial.
Topics: Body Mass Index; Bupropion; Depression; Dopamine Uptake Inhibitors; Health Behavior; Humans; Life St | 2006 |
Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Delirium; Depressi | 2006 |
Bupropion therapy for pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; Gambli | 2007 |
Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
Topics: Animals; Antidepressive Agents, Second-Generation; Arginine; Behavior, Animal; Body Temperature; Bra | 2007 |
Bupropion-induced parkinsonism.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Humans; Male; Middle Aged; Parkinso | 2007 |
Treatment of comorbid attention deficit hyperactivity disorder and depression in pediatric patient.
Topics: Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bupropion; | 2007 |
[Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Bupropion; Controlled Clinical Trials a | 2007 |
Prolonged QT associated with an overdose of trazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Drug Overdose; Electrocardio | 2007 |
New directions in the treatment of depression: bupropion.
Topics: Antidepressive Agents; Bupropion; Depression; Humans; Propiophenones | 1983 |
Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection.
Topics: Bupropion; Chromatography, High Pressure Liquid; Depression; Humans; Propiophenones; Spectrophotomet | 1984 |
A clinical trial of bupropion in the treatment of depressed outpatients.
Topics: Adult; Aged; Ambulatory Care; Bupropion; Cognition Disorders; Depression; Drug Evaluation; Drug Inte | 1984 |
Two multicenter studies of the antidepressant effects of bupropion HCl versus placebo.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Depression; Double-Blind Method; Drug Eva | 1980 |
Absence of orthostatic hypotension in depressed patients treated with bupropion.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Blood Pressure; Bupropion; Depression; Ele | 1981 |
Excretion of bupropion in breast milk.
Topics: Adult; Breast Feeding; Bupropion; Depression; Female; Humans; Infant; Male; Milk, Human | 1993 |
Eosinophilia associated with bupropion.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Eosinophilia; Female; Humans; | 1995 |
Serum sickness induced by bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Middle Aged; Psycho | 1999 |
Amphetamine positive toxicology screen secondary to bupropion.
Topics: Aged; Amphetamine; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Chromatogr | 2000 |
[Successful treatment of depression in a Parkinson disease patient with bupropion].
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; F | 2000 |
Bupropion-induced acute dystonia.
Topics: Acute Disease; Adult; Bupropion; Buspirone; Depression; Dopamine Uptake Inhibitors; Dose-Response Re | 2002 |
Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department.
Topics: Adult; Alcohol Withdrawal Seizures; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; A | 2002 |
Bupropion.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Administration Schedule; Humans; Propiophenones | 1991 |
Antidepressant profile of bupropion and three metabolites in mice.
Topics: Animals; Antidepressive Agents; Apomorphine; Body Temperature; Bupropion; Depression; Male; Mice; Mo | 1990 |
Bupropion reintroduced for treatment of depression.
Topics: Antidepressive Agents; Bupropion; Depression; Humans; Propiophenones | 1989 |